Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against Elevance Health, Inc.. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Why Is Elevance Health, Inc. (ELV) Under Investigation?
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elevance Health, Inc. (“Elevance” or “the Company”) (NYSE: ELV). Investors who purchased Elevance securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Elevance has violated federal securities laws.
What Potential Securities Violations Is BG&G Investigating?
On March 2, 2026, Elevance disclosed in a filing with the U.S. Securities and Exchange Commission that it “was notified by the Centers for Medicare & Medicaid Services (‘CMS’) of its intent to impose intermediate sanctions suspending enrollment of Medicare beneficiaries into the Company’s Medicare Advantage-Prescription Drug (‘MA-PD’) plans and suspending certain communication activities to Medicare beneficiaries.” Elevance said that “CMS has indicated that the proposed sanctions relate to alleged noncompliance by the Company with certain Medicare Advantage risk adjustment data submission requirements for dates of service prior to April 3, 2023” and that “[t]he sanctions are scheduled to take effect on March 31, 2026 unless CMS determines that the issues identified have been satisfactorily addressed.” Following this news, Elevance’s stock price fell $25.93 per share, or 8.1%, to close at $294.07 on March 2, 2026.
What Should Elevance Health, Inc. (ELV) Investors Do?
If you are aware of any facts relating to this investigation or purchased Elevance securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
How Did Elevance Health, Inc. (ELV) Stock React?
How Does BG&G Help Investors in Securities Fraud Investigations?
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”